Next 10 |
home / stock / bnoef / bnoef news
The following slide deck was published by Bionomics Limited in conjunction with this event. For further details see: Bionomics (BNOX) Investor Presentation - Slideshow
Bionomics Limited Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs in the United States PR Newswire EASTWOOD, Australia , Jan. 5, 2022 /PRNewswire/ -- Bionomics Limited ( Bionomics or Company ), a clinical-stage biopharmaceutica...
Bionomics Limited Announces Pricing of Initial Public Offering in the United States PR Newswire ADELAIDE, Australia , Dec. 16, 2021 /PRNewswire/ -- Bionomics Limited ( Bionomics or Company ), a clinical-stage biopharmaceutical company, today announced the...
Bionomics (OTCQB:BNOEF) announces that the FDA has granted Fast Track designation to the BNC210 development program for the acute treatment of Social Anxiety Disorder (SAD) and other anxiety-related disorders. Fast Track status provides for more frequent interaction with the FDA review team a...
U.S. FDA Grants Bionomics Fast Track Designation to BNC210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders PR Newswire ADELAIDE, Australia , Dec. 1, 2021 /PRNewswire/ -- Bionomics Limited (ASX:BNO, OTCQB:BNOEF) ( Bion...
Bionomics, an Australian Phase 2 biotech developing allosteric ion channel modulators for CNS disorders, filed for an initial public offering up to $25M with the U.S. Securities and Exchange Commission. The company's shares currently trade on the Australian Securities Exchange ...
Bionomics Files Registration Statement for Proposed Initial Public Offering in the United States PR Newswire ADELAIDE, Australia , Nov. 23, 2021 /PRNewswire/ -- Bionomics Limited (ASX:BNO, OTCQB:BNOEF) ( Bionomics or Company ), a clinical-stage biopharmac...
Bionomics Limited (OTCQB:BNOEF) has received U.S. FDA clearance to proceed with evaluating its lead clinical compound, BNC210, for the acute treatment of Social Anxiety Disorder (SAD) in a Phase 2 trial. BNC210 is an oral proprietary selective negative allosteric modulator of the α...
Bionomics Receives FDA Clearance of IND for Evaluation of BNC210 in a Phase 2 Social Anxiety Disorder PREVAIL Study PR Newswire U.S. FDA clearance of IND for BNC210 evaluation as an acute treatment for patients with Social Anxiety Disorder in a Phase 2 clinical trial...
The excitement from FDA approval of Biogen’s Alzheimer’s drug Aduhelm is subsiding. The FDA is being scrutinized about the approval, and key hospitals are not prescribing Aduhelm. The fall in Biogen share price reflects Aduhelm seen as not an effective treatment for ...
News, Short Squeeze, Breakout and More Instantly...
Bionomic Ltd Par Ord Company Name:
BNOEF Stock Symbol:
OTCMKTS Market:
Bionomics Limited Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs in the United States PR Newswire EASTWOOD, Australia , Jan. 5, 2022 /PRNewswire/ -- Bionomics Limited ( Bionomics or Company ), a clinical-stage biopharmaceutica...
Bionomics Limited Announces Pricing of Initial Public Offering in the United States PR Newswire ADELAIDE, Australia , Dec. 16, 2021 /PRNewswire/ -- Bionomics Limited ( Bionomics or Company ), a clinical-stage biopharmaceutical company, today announced the...
U.S. FDA Grants Bionomics Fast Track Designation to BNC210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders PR Newswire ADELAIDE, Australia , Dec. 1, 2021 /PRNewswire/ -- Bionomics Limited (ASX:BNO, OTCQB:BNOEF) ( Bion...